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ABSTRACT
Purpose Imaging methods were used as tools to provide an
understanding of phenomena that occur during dissolution
experiments, and ultimately to select the best ratio of two
polymers in a matrix in terms of enhancement of the dissolu-
tion rate and prevention of crystallization during dissolution.
Methods Magnetic resonance imaging, ATR-FTIR spectro-
scopic imaging and Raman mapping have been used to study
the release mechanism of a poorly water soluble drug,
aprepitant, from multicomponent amorphous solid disper-
sions. Solid dispersions were prepared based on the combina-
tion of two selected polymers - Soluplus, as a solubilizer, and
PVP, as a dissolution enhancer. Formulations were prepared
in a ratio of Soluplus:PVP 1:10, 1:5, 1:3, and 1:1, in order to
obtain favorable properties of the polymer carrier.
Results The crystallization of aprepitant during dissolution
has occurred to a varying degree in the polymer ratios 1:10,
1:5, and 1:3, but the increasing presence of Soluplus in the
formulation delayed the onset of crystallization. The
Soluplus:PVP 1:1 solid dispersion proved to be the best matrix
studied, combining the abilities of both polymers in a syner-
gistic manner.
Conclusions Aprepitant dissolution rate has been significantly
enhanced. This study highlights the benefits of combining
imaging methods in order to understand the release process.
KEYWORDS amorphous solid dispersion . confocal Raman
spectroscopy . crystallisation . FT-IR spectroscopic imaging .
magnetic resonance imaging
ABBREVIATIONS
ATR-FTIR Attenuated total reflection-Fourier
transform infrared spectroscopy
BCS Biopharmaceutics classification system
DSC Differential scanning calorimetry
DVS Dynamic vapour sorption
FTIR Fourier transform infrared
spectroscopy
HPLC High performance liquid
chromatography
MRI Magnetic resonance imaging
MSME Multi slice multi echo
MTDSC Modulated temperature
differential scanning calorimetry
PVP Polyvinylpyrrolidone
USP United States pharmacopeia
UV Ultraviolet
XRD X-ray diffraction
INTRODUCTION
Amorphous solid dispersions are widely used to enhance dis-
solution rates and absorptions of orally administered formu-
lations of poorly water-soluble drugs. The formation of an
amorphous solid dispersion involves the combination of two
or more chemically distinct components – typically a poorly
soluble, hydrophobic drug and a readily soluble, hydrophilic
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polymer – into a single matrix (1–3). Amorphous solid disper-
sions can be formed either by mixing the components in the
molten state, followed by cooling (e.g. hot-melt extrusion pro-
cess), or by dissolving them in a common solvent, followed by
rapid evaporation (e.g. spray drying process). Depending up-
on the nature of the components and their ratio in the matrix,
pharmaceutical formulations based on amorphous solid dis-
persions can suffer from thermodynamic instability, resulting
in unexpected crystallization of the drug in the solid state
during storage or during dissolution. Consequently, this
causes a reduction in the amount of the drug bioavailability
(4,5).
The dissolution of tablets formed from amorphous solid
dispersions is a relatively complex process where several phe-
nomena occurr simultaneously (6). These include the hydra-
tion, water ingress, swelling and erosion of the polymer ma-
trix, as well as the diffusion of the drug across the swollen gel
l aye r and in to the bu lk so lu t ion . As the loca l
drug:polymer:solvent ratio varies in different regions of the
dissolving tablet, due to different diffusion coefficients of each
component, the drug can reach a locally supersaturated state
that leads to crystallization. The crystallization (nucleation
and crystal growth) is influenced by multiple factors such as
the degree of supersaturation, the viscosity of the polymer gel,
and the interfacial energy between the crystal nuclei and the
solvent (7). In this context, the polymer plays an important
role as it can keep the drug in the supersaturated state and
therefore inhibit or delay crystallization (5) through a combi-
nation of viscosity and surface-energy effects.
From a design of formulation perspective, the selec-
tion of the most suitable polymers must reflect process-
ability during the preparation of amorphous solid dis-
persions, stability of the amorphous form of drug during
storage, and the ability to control drug release and in-
hibit crystallization during dissolution (8–10). Often, a
single polymer will not guarantee all the above-
mentioned properties simultaneously. For example, al-
though polymers with a strong affinity towards the drug
molecules via hydrogen bonding or hydrophobic inter-
actions could be effective at preventing crystallization
(11–16), they might at the same time restrict the ingress
of water into the tablet, resulting in sub-optimal release
profiles.
In our recent work (9,17,18), we have shown that both
Soluplus (an amphiphilic polymer) and polyvinylpyrrolidone
(PVP) were able to form stable amorphous solid dispersions
with aprepitant at a drug:polymer ratio of 1:3 by weight.
However, neither polymer alone could provide an ideal drug
release profile. While Soluplus was able to suppress crystalli-
zation, the release rate was limited by the slow diffusion of
water into the matrix. On the other hand, the release of
aprepitant from a PVP matrix was way too fast, resulting in
crystallization of the drug. Therefore, it was suggested that a
combination of polymers with different (even opposite) prop-
erties in a mixed matrix could result in the favorable charac-
teristics from each of the components in the final formulation
(19,20).
In order to rationalize the selection of polymers for the
mixed-matrix formulations, it is important to understand the
underlying mechanism of drug release and the molecular in-
teractions between individual components during dissolution.
To this end, it is beneficial to combine standard USP-type
dissolution tests with chemically specific, spectroscopic
imaging-based analytical approaches such as attenuated total
reflection-Fourier transform infrared (ATR-FTIR) spectro-
scopic imaging (21–24), magnetic resonance imaging (MRI)
(25,26), UV imaging (27,28) and Raman imaging (29,30).
These techniques allow the visualization of dynamic physico-
chemical processes within a tablet under dissolution condi-
tions, making it possible to elucidate phenomena that could
not be easily identifiable from the USP release curve. Since
each imaging method is based on different physical principles
with a corresponding difference in the chemical, spatial and
temporal resolution, their combination may be necessary to
reveal a full picture of the dissolution process (17,31,32).
The aim of the present work is to demonstrate – for the first
time – the combination of three chemical imaging methods
(MRI, ATR-FTIR spectroscopic imaging, and confocal
Raman mapping) in order to understand the behaviour of
drug release from amorphous solid dispersion in a mixed poly-
mer matrix. Each imaging method provides a different view
(in terms of spatial information and chemical specificity) of the
dissolving tablet (Fig. 1). Using specific model formulations
containing aprepitant as the drug with Soluplus and PVP as
polymers, we show that a wealth of information can be gained
about the dissolving tablets using a combination of these ap-
proaches to reveal insight about drug relase that none of the
Fig. 1 Scheme of image positions relative to the tablet, provided by each
imaging method used in this work.
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methods can provide individually. We can design a formula-
tion such that the drug relase rate from the mixed polymer
matrix is faster than from either of the polymers alone, and at
the same time the crystallisation of the drug is suppressed.
MATERIALS AND METHODS
Materials
The drug aprepitant was kindly provided by Zentiva, k.s.
(Prague, Czech Republic). Aprepitant is a poorly water-
soluble drug (category II) according to the Biopharmaceutics
Classification System (BCS) criteria. Two different polymers
were used as matrix materials for the amorphous solid disper-
sions. Polyvinylpyrrolidone K30 (PVP), obtained from BASF
(Germany), is a water soluble polymer with a molecular
weight of 30 000 g/mol. Soluplus (polyvinyl caprolactam–
polyvinyl acetate–polyethylene glycol graft copolymer), ob-
tained from BASF (Germany), is an amphiphilic, solubility
enhancing excipient with an average molecular weight of
118 000 g/mol.
Preparation of Solid Dispersions
Amorphous solid dispersions were prepared by spray drying.
The drug:polymer ratio in the solid dispersions was fixed at
1:3 by weight, where the polymer matrix was composed of
systematically varying Soluplus:PVP ratios ranging from 1:0,
1:1, 1:3, 1:5, 1:10 to 0:1. To prepare the amorphous disper-
sion, aprepitant (1.0 g) was dissolved in ethanol (150 ml), the
solution was mixed at 40°C for 15 min, and the required
amount of the polymers was added until complete dissolution
to achieve an overall drug:polymer ratio of 1:3 w/w. The
solution was spray dried using the Mini Spray Dryer B-290
(Büchi, Switzerland) with an inert nitrogen loop. The spray-
dried particles were subsequently compressed to tablets
(140 mg, round flat shape, 7 mm in diameter) at a compres-
sion force 5 kN. In addition to a formulation where both
polymers and the drug were spray dried together, tablets com-
pressed from a physical blend of spray dried amorphous solid
dispersion made of aprepitant:PVP in ratio 1:3, and admixed
spray dried particles of pure Soluplus, were formed.
Differential Scanning Calorimetry
The glass transition temperatures of the solid dispersions were
measured by modulated temperature differential scanning
calorimetry (MTDSC) immediately after preparation. DSC
measurements were performed on a TA Instruments,
Discovery DSC apparatus. The samples were weighed in alu-
minum pans (40 μl), covered and measured in a nitrogen flow.
Investigations were performed in a temperature range of 0 to
300°C with a heating rate of 5°C/min (amplitude = 0.8°C,
period = 60 s). The average weight of the sample was approx-
imately 4–5 mg.
Magnetic Resonance Imaging
The Magnetic Resonance Imaging (MRI) Desktop System
Icon (Bruker BioSpin, Germany) was used to observe the wa-
ter ingress into tablets and structural changes in the gel layer
during dissolution. The MRI analysis was based on multi-
slice-multi-echo (MSME) sequences with echo time 25 ms,
repetition time 1500 ms, number of averages 2, number of
repetitions 1. The images were weighted by relaxation times
T1. The resolution of the images was 128 × 128 pixels for a
field of view 1.8 × 1.8 cm. The slice thickness was 1 mm. The
first scan was used to localize the position of the tablet in the
flow cell and choose the number, position and thickness of
slices. The dissolution medium was water at a flow rate of
5 ml/min and room temperature. The scans were taken every
8 min. Further details of the experimental set-up can be found
in (33).
Attenuated Total Reflection Fourier Transform Infrared
(ATR-FTIR) Spectroscopy and Spectroscopic Imaging
FTIR spectra for all of the pure material and formulations
studied in this investigation were measured using an Alpha-P
spectrometer (Bruker, UK) in ATR mode, fitted with a dia-
mond crystal. Spectra were recorded across the range of
4000–600 cm−1, using a spectral resolution of 8 cm−1 and
32 co-added scans.
To collect ATR-FTIR spectroscopic images of the dissolv-
ing tablet compacts, an ATR accessory (Pike, USA) fitted with
a zinc selenide (ZnSe) crystal was employed. This ATR acces-
sory was placed in an IMAC sampling compartment that was
attached to an FTIR spectrometer (Equinox 55, Bruker) and
the imaging data was recorded using a focal plane array (FPA)
detector. Spectra in the mid-IR region between 4000 and
900 cm−1 was recorded for all of the dissolution experiments
using a spectral resolution of 8 cm−1 and 32 co-added scans.
The FPA detector was setup to record an array size of 96 ×
96 pixels, meaning that 9216 individual FTIR spectra were
recorded in a single experiment. This resulted in spectroscopic
images with dimensions of approximately 7.75 × 6.05 mm2
and a spatial resolution of 100–150 μm (34).
The measuring surface of the ZnSe crystal has a diameter
of 20 mm which allowed one to obtain information from the
entire 3 mm tablet as well as the surrounding solution.
Spectroscopic images representing the spatial distribution of
the different components during the experiment were gener-
ated based on the identification of specific absorption bands
for each of the materials of interest. Subsequently, the inte-
grated absorbance of these spectral bands was plotted as a
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function of the measured area. Table I shows the integration
ranges of spectral bands used to generate the spectroscopic
images of the different components of interest in this investi-
gation. The spectral band integration method used draws a
linear baseline between the frequency limits defined in Table I
and the area above this line is integrated. It should be realised
that red regions in the spectroscopic images relate to high
absorbance and the blue areas relate to low absorbance of
the species.
Dissolution Methodology Under ATR-FTIR
Spectroscopic Imaging
The dissolution experiments were setup by positioning the
tablet compact in the centre of the 20 mm ZnSe crystal. A
custom designed Perspex flow cell (35) placed above the tablet
and a rubber O-ring was used to form a seal between the
ZnSe crystal and the flow cell. Furthermore, the Perspex flow
cell was used to provide sufficient pressure from the top of the
tablet tablet (3 mm in diameter) that allowed contact to be
achieved that allowed contact to be achieved between the
sample and the ATR crystal. Good contact is needed for col-
lection of reliable spectral information when using the ATR
sampling methodology since the penetration of the evanescent
IR beam is typically up to 10 μm beyond the surface of the
crystal.
The dissolution medium (distilled water) was pumped
through the flow cell at a rate of 5 ml/min. It should be
realised that when using this setup the tablet compact is
sandwiched between the flow cell and the measuring surface
of the ZnSe crystal, meaning that the dissolution medium only
contacts the side, not the top or bottom, surface of the tablet.
Raman Spectroscopy
The spectra of pure components were measured by the inVia
Reflex confocal Raman microscope (Renishaw, UK) at an
excitation wavelength of 785 nm (operated at laser power of
50 mW) with an integration time of 0.5 s. The spectral range
was 1800–730 cm−1 and the spectra were obtained from
amorphous spray dried powder or the initial crystalline drug.
Raman Mapping
In situ dissolution behavior of amorphous solid dispersions was
studied using the inVia Reflex confocal Raman microscope
(Renishaw, UK) with a specifically designed cells enabling the
measurement of dissolution under water in stagnant condi-
tions or under flow (for details of the flow cell, see
Supplementary Information 1). The dissolution medium was
distilled water at room temperature and a flow rate of 5 ml/
min. The x-y surface area scans were used to measure the
possible crystallization of aprepitant during dissolution every
5 min. By focusing on the surface of the tablet at each time
interval (the tablet swells or dissolves upon dissolution, there-
fore the z-coordinate of the imaging area must be adjusted), x-
y surface area scans (20 × 20 μm2), with a 2 μm step size using
a 48× immersion objective were performed. Subsequently,
the spectral data sets were background and cosmic rays
corrected, processed by the intensity of unique bands of amor-
phous (1007 cm−1) and crystalline (1043 cm−1) aprepitant,
and converted to false-color images by the software Wire 4.1.
USP Dissolution Testing
In addition to imaging-based dissolution experiments (MRI,
ATR-FTIR spectroscopic imaging, Raman mapping), stan-
dard in vitro dissolution testing was performed according to
the United States Pharmacopeia (USP) type I method. The
dissolution tests were conducted using a Sotax semi-
automated system (Sotax AT7) with a validated analytical
method (HPLC Waters 2695 Alliance with UV detection).
The samples were filtered using a single filter with a pore size
of 40 μm. The dissolution profile was measured with baskets
at 100 rpm in 150 ml of distilled water at room temperature.
The concentration of aprepitant in the solution was deter-
mined at sampling intervals ranging from 30 to 120 min for
a period of up to 510 min.
RESULTS AND DISCUSSION
Solid State Characterization of the Solid Dispersions
The amorphous nature of the formulations prepared as de-
scribed in section 2.2, where the drug is molecularly dispersed
in the polymer matrix, was confirmed by DSC analysis. The
glass transition temperatures of the spray-dried materials with
varying composition of the polymer matrix were 138.0, 135.4,
134.0, and 127.9°C for a Soluplus:PVP ratio of 1:10, 1:5, 1:3,
and 1:1, respectively. Usually, the Tg curve obeys the
Gordon–Taylor equation. Tg decreases from the pure PVP
Table I The Specific Integration Ranges of Spectral Bands Used to
Generate ATR-FTIR Spectroscopic Images for the Different Components of
Interest in this Investigation
Components Integration range/cm−1 Spectral band peak/cm−1
Crystalline aprepitant 985–1010 998
Soluplus 1215–1250 1224
PVP 1305–1330 1313
Water 3000–3600 3300
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with Tg 159.5°C to pure polymer Soluplus (Tg 68.2°C) de-
pending on the ratio of both polymers in carrier. Tg of amor-
phous pure Aprepitant is 93.3°C. It should be realized that the
aprepitant:polymer ratio was kept constant in all cases, i.e. the
above ratios refer to the composition of the polymer matrix
only, which represents 75% of the formulation on a mass
basis. As reported in our previous work (18), the glass transi-
tion temperatures of solid dispersions with pure polymers were
142.9 and 57.8°C in the case of aprepitant:PVP and
aprepitant:Soluplus, respectively.
Magnetic Resonance Imaging (MRI)
MRI analysis enables the observation of phenomena at the
length-scale of the whole tablet in the 3D space. Hence, the
behavior of the tablet is not restricted by the close physical
proximity of the experimental setup such as the contact with
an ATR crystal when performing ATR-FTIR spectroscopic
imaging studies. Specifically, MRI enables the observation of
water ingress into the tablet, polymer swelling and erosion, as
well as potential structural changes in the hydrated polymer
layer. The evolution of the tablet structure in two cases
(Soluplus:PVP ratio 1:10 and 1:1), visualized by MRI, is sum-
marized in Fig. 2. The combination Soluplus:PVP 1:10
(Fig. 2a) shows a recognizable dry core and the formation of
a gel layer of increasing thickness during dissolution. The gel
layer contains a higher concentration of hydrogen atoms as-
sociated with water, corresponding to longer relaxation times.
In contrast, the dry core of the tablet is characterized by very
short relaxation times, indicated by dark (black) color in the
color scale used in Fig. 2. Details of the gel layer are shown in
Fig. 3a and b. Interestingly, the detailed view (Fig 3b) reveals
the occurrence of small regions with shorter relaxation times
that can be clearly detected after 110 min of dissolution in the
gel layer. It can be hypothesized that these regions correspond
to a newly formed solid phase. During the dissolution of amor-
phous solid dispersions, the drug can become locally supersat-
urated in the gel layer and crystallize. Since magnetic reso-
nance imaging is not a suitable method to identify chemically
specific information about the particles, the exact nature of the
particles has to be identified by other imaging methods.
In contrast, the polymer carrier with a Soluplus:PVP ratio
1:1 shows a substantially lower rate of tablet hydration
(Fig. 2b). No gel layer is formed around the tablet after contact
with water within the 140 min time frame of the experiment
(Fig. 3d). It seems that water penetrates to the tablet preferen-
tially through cracks formed during dissolution (upper right-
hand corner of the tablet in Fig. 2b). The lower hydration rate
of the tablet can be attributed to lower hygroscopicity of
Soluplus, which represents a higer proportion of the polymer
matrix in this case. Crucially, MRI did not indicate any crys-
tallization processes during the dissolution of tablets made
with a Soluplus:PVP ratio 1:1 (Fig. 3d).
ATR-FTIR Spectroscopic Imaging
ATR-FTIR spectroscopic imaging has a significant advantage
of providing chemically specific information about the solid
dispersion components. It simultaneously measures thousands
of infrared spectra and provides spatially resolved quantitative
information about the concentration of the individual compo-
nents in the measured area. A potential disadvantage of ATR-
FTIR spectroscopic imaging is the need to physically press the
tablet against the ATR crystal, which may influence the nat-
ural dissolution mechanisms by constraining water ingress and
gel layer formation to just the outside surface of the tablet.
The structural change of a drug from an amorphous
state to its crystalline form can influence its infrared
spectrum. The comparison of ATR-FTIR spectra of
the amorphous and crystalline form of aprepitant is
Fig. 2 Images of whole-tablet dis-
solution obtained by MRI. The
composition of the polymer matrix
was (a) Soluplus:PVP 1:10, and (b)
Soluplus:PVP 1:1.
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shown in Fig. 4. Two significant spectral changes be-
tween the structural forms are the appearance of the
band at 998 cm−1 and the narrowing of the band at
1700 cm−1. These differences in the spectrum can be
used to characterize and detect the crystallization from
the amorphous solid dispersion. Thus, it is feasible that
this approach can complement the initial observations of
the MRI by confirming the presence of any structural
changes during the tablet dissolution experiment. ATR-
FTIR spectroscopic imaging also provides insight into
possible causes of crystallization. Local supersaturation
of the drug, which is a pre-requisite of crystallization,
can be caused by the local depletion of a polymer that
originally stabilised the amorphous form (18). Due to
the high chemical specificity of ATR-FTIR spectroscop-
ic imaging is it possible to reveal changes in the local
polymer concentrations during dissolution by selection
of unique absorption bands for these components.
ATR-FTIR spectroscopic images representing the
spatial distribution of the two polymers used in the
amorphous solid dispersion with carrier made of
Soluplus:PVP 1:5, and the water penetration into the
tablet compact during dissolution are shown in Fig. 5.
PVP (top row) is dissolved rapidly from the tablet im-
mediately after contact with water. After 70 min of
dissolution, there is almost no PVP remaining in the
tablet and it is almost entirely wet. The penetration of
water (bottom row) into the tablet compact is coincident
with the loss of PVP. Thus, it is evident that PVP read-
ily dissolves in spite of the presence of other compo-
nents in the amorphous solid dispersion. The high
amount of PVP in the solid dispersion significantly
Fig. 3 Detail of the interface
between the tablet surface during
the dissolution experiments
obtained by MRI, for polymer
matrix compositions and times as
indicated in the panels.
Fig. 4 ATR-FTIR spectra recorded
from measurement of pure
crystalline and amorphous
aprepitant. Two significant spectral
changes between the structural
forms, the appearance of the band
at 998 cm−1 and the narrowing of
the band at 1700 cm−1, are
highlighted.
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improves the water penetration rate but at the same
time, its rapid depletion can result in a high local su-
persaturation of the drug. Soluplus (middle row) forms a
gel layer after water penetration into the tablet. In con-
trast to PVP, only a slow depletion of Soluplus concen-
tration was observed in 70 min.
It can be expected that the depletion rate of PVP from the
mixed polymer matrix would depend on the ratio of the two
polymers. The depletion process depends on the rate of hy-
dration, polymer chain disentanglement and diffusion of each
polymer through the composite matrix.
In order to establish the extent to which the dissolution and
depletion of PVP from the tablet matrix leads to crystallization
of the drug, ATR-FTIR spectroscopic images based on the
characteristic spectral bands of the crystalline form of
aprepitant were compared for Soluplus:PVP ratios ranging
from 1:1 to 1:10. The ATR-FTIR spectroscopic images
(Fig. 6a) reveal the occurrence of crystalline aprepitant in all
formulations except that with a Soluplus:PVP ratio 1:1 (bot-
tom row in Fig. 6a) where no crystalline phase was detected
even after 180 min of dissolution. In those cases where
aprepitant crystallization did occur, the quantity of the crys-
talline phase and its spatial distribution varied as function of
the Soluplus:PVP ratio in the polymer matrix. For the lowest
Soluplus:PVP ratio 1:10, a single nucleation event seems to
have occurred at a point indicated by the crosshair (Fig. 6a,
top row, t = 30 min), from which a growing cluster of the
crystalline phase agglomerates. The ATR-FTIR spectra ex-
tracted from the spectroscopic images recorded from that
point at different times are depicted in Fig. 6b. The spectral
changes, in particular the appearance of unique bands at 998
and 1770 cm−1, indicate the local crystallization of aprepitant
in the region of interest. The formation of a distinct crystalline
phase shown in Fig. 6a and confirmed in the extracted spectra
in Fig. 6b can be regarded as a proof that the solid particles
apparent in the MRI sequence (Figs. 2a and 3b) were indeed
aprepitant crystals.
For the Soluplus:PVP ratio 1:5, the crystalline phase occurs
more symmetrically in a circular region corresponding to the
periphery of the original tablet (Fig. 6a). The intensity is lower
(despite identical drug load in the tablet), meaning that
crystallisation was partially suppressed. Increasing the
Soluplus:PVP ratio to 1:3 results in a further delay of the onset
of crystallization, to a point that the crystalline phase no longer
forms a hollow circular ring, but is restricted to a central area
of the original tablet. Finally, the highest Soluplus:PVP ratio
1:1 was able to suppress crystal formation altogether beyond
180 min, which is again complementary to the observations
made using MRI (Figs. 2b and 3d).
The formation of solid particles in the gel layer was ob-
served by MRI in the previous section and identified by
ATR-FTIR spectroscopic imaging as the crystalline form of
aprepitant. However, the spatial localization of the crystalliza-
tion event in the case of the Soluplus:PVP ratio 1:10 is indic-
ative of a possible heterogeneous nucleation, which could be
influenced by the physical presence of the ATR crystal.
Heterogeneous nucleation typically occurs at lower supersat-
uration levels than homogeneous nucleation. Therefore, the
crystallization of aprepitant could be initiated and observed
sooner in the ATR-FTIR spectroscopic images because of the
experimental setup in which the tablet is in direct contact with
the ATR crystal that may provide nucleation points. This is in
contrast to a tablet in an unrestricted environment such as the
MRI dissolution cell (cf. Fig. 2). Furthermore, the spatial
Fig. 5 ATR-FTIR spectroscopic images of tablet compact from amorphous dispersion (ratio 1:5) during dissolution. Images representing the spatial distribution of
the two polymers used in the formulations, PVP (top row) and Soluplus (middle row), and the penetration of water (bottom row) into the tablet compact. The
dimensions of the images are approximately 7.75× 6.05 mm2.
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resolution of ATR-FTIR images is 100–150 μm for the spe-
cific optical configuration used in this study, so any initial
crystallization sites forming that are significantly smaller than
this size may not be resolved.
Raman Microscopy
The experimental setup of the dissolution cell in Section 2.8
makes it possible to observe any structural changes (particu-
larly drug crystallization) at the free tablet surface in contact
with the dissolution medium. The surface of the tablet is not
limited for water penetration or dissolution of drug, and there
is no foreign surface for preferred heterogeneous nucleation.
Differentiation of the amorphous and crystalline form of drug
was achieved based on their individual Raman spectra.
Unique bands used for the differentiation of the amorphous
drug, crystalline drug, Soluplus and PVP were 1005, 1047,
1450 and 935 cm−1, respectively, similarly to those described
in (18).
False-color images based on the Raman spectra obtanied
from x-y scans of the tablet surface are shown in Fig. 7a.
Crystallization was identified after 20 min for the
aprepitant:PVP matrix (i.e. when no Soluplus is added to
the formulation). The increased weight loading of Soluplus
in the carrier delays the onset of crystallization of aprepitant
to 40, 160, and 240 min for the Soluplus:PVP ratio of 1:10,
1:5, and 1:3 solid dispersions, respectively. Crystallization of
aprepitant was not observed in the polymer matrix based on
Fig. 6 (a) ATR-FTIR spectroscopic
images showing the presence of
crystalline aprepitant that appeared
during the dissolution of the tablet
compacts prepared using formula-
tions with a varying Soluplus:PVP
ratio as indicated. The dimensions
of the images are approximately
7.75× 6.05 mm2. (b) ATR-FTIR
spectra extracted from the same
location during dissolution of the
carrier with Soluplus:PVP 1:10. The
specific location is indicated by the
crosshair in case a). The appearance
of spectral bands indicative of the
formation of crystalline aprepitant, at
998 and 1770 cm−1, as the exper-
iment progressed, are highlighted.
Punčochová et al.
Soluplus:PVP ratio of 1:1 (bottom row in Fig. 7a) throughout
240 min of dissolution. The appearance of spectral bands at
1047 and 1574 cm−1, which is indicative of formation of crys-
talline aprepitant during dissolution, is represented in Fig. 7b.
The results from the Raman mapping follow those from the
other spectroscopic imaging approaches, that Soluplus is respon-
sible for the suppression or crystallization in the mixed polymer
matrix. The question is whether the effect of Soluplus on the
inhibition of crystallization depends on the manner in which
Soluplus is incorporated into the tablet matrix. To find out, we
have compared formulations without Soluplus (aprepitant:PVP
1:3), with Soluplus directly incorporated into the spray-dried
solution, and a tablet matrix composed of admixed spray dried
particles of pure Soluplus with solid dispersion particles contain-
ing aprepitant:PVP 1:3. The examples of false-color Raman
images (Fig. 8) show that the amorphous solid dispersion without
Soluplus had significantly crystallized by 35 min (top row). On
the other hand, the presence of Soluplus in the carrier (bottom
row) can inhibit the crystallization of aprepitant. Interestingly,
admixed Soluplus (middle row), which is not present directly in
the amorphous solid dispersion of the drug, is also able to sup-
press crystallization in local regions for 3 h. However, this sup-
pression is not uniform as in the case of co-spray dried Soluplus
and PVP, but rather only in specific regions where other areas
show the crystallization of aprepitant after 35 min, which is a
comparable timeframe to the crystallization in aprepitant:PVP
1:3 without Soluplus.
From the formulation perspective, the inhibition of
aprepitant crystallization is possible even with admixed
Soluplus. However, the amount of admixed Soluplus in the
final formulation would have to be significantly higher than
the amount of Soluplus in the solid dispersion carrier in order
to achieve comparable inhibition of crystallization (for details
of the effect of admixed Soluplus, see Supplementary
Information 2).
USP Dissolution Testing
The USP dissolution profiles of aprepitant from the amor-
phous solid dispersions in pure polymers and their
Fig. 7 (a) Raman imaging of how
the distribution of the crystalline
aprepitant changes during
dissolution (x-y surface area scans
covering 20× 20 μm2). The false-
color images depict the solid dis-
persions of each combination in
dark blue, and pure crystalline drug
in pink, respectively. (b) Raman
spectra extracted from the same
location of the images during disso-
lution of tablets with a Soluplus:PVP
ratio 1:10. The appearance of
spectral bands indicative of the for-
mation of crystalline aprepitant, at
1047 and 1574 cm−1, as the ex-
periment progressed are
highlighted.
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combinations are shown in Fig. 9. The dissolution profile from
the pure Soluplus matrix (yellow points) is rather slow, but
controlled. Aprepitant dissolution from a pure PVP matrix
(red points) was very fast during the first 60 min but then
slowed down, to a similar dissolution rate as the pure
Soluplus matrix until 480 min. After approx. 480 min,
aprepitant precipitation was manifested by a decrease in its
concentration in the dissolution medium. The equilibrium
solubility of aprepitant in both PVP and Soluplus solutions
was measured, and found to be below 0.20 mg/l (detection
limit of the HPLC method) for PVP (polymer concentration
800 mg/l, which corresponds to a fully dissolved tablet), and
1.31mg/l for Soluplus (800mg/l polymer concentration) (18).
This means that the solution was supersaturated with respect
to aprepitant, as shown in Fig. 9.
The multicomponent carriers of the solid dispersions,
namely the ratio 1:10, 1:5, and 1:3, show a slow drug dissolu-
tion rate that is very similar to dissolution from the pure
Soluplus matrix. However, after approx. 360 min, the disso-
lution rate of aprepitant was observed to slow down even
further. The most ideal dissolution profile for Aprepitant
was obtained for the combination Soluplus:PVP 1:1, where
the dissolution rate of drug is considerably enhanced.
Dissolution rate during the first 60 min is as fast as that from
pure PVP, but this trend continues throughout the duration of
the experiment and does not slow down even after 480min. In
this combination, the favorable properties of both polymers
are manifested. The solubilisation effect of Soluplus inhibits
drug precipitation in solution, while PVP improves the disso-
lution rate by its fast dissolution from the carrier.
CONCLUSION
The combination of three spectroscopic imaging methods
MRI, ATR-FTIR spectroscopic imaging, and Raman map-
ping were succesfully employed to understand the mechanism
of drug release frommulticomponent amorphous solid disper-
sions. Each approach was found to complement each other
and reveal important information about the tablet dissolution
process. Specifically,MRI provides information about the rate
of dissolution medium penetration into the tablet and the
kinetics of swelling and erosion of the gel layer. ATR-FTIR
spectroscopic imaging makes it possible to distinguish and
characterise the individual components that make up the tab-
let formulation, including the structural form of the API and
individual excipients. It provides information about the evo-
lution of concentration profiles within the tablet and reveals
the diffusion rate of the individual components through the
tablet matrix. Raman imaging provies information about the
Fig. 9 USP dissolution profiles of aprepitant from tablets compressed of
spray-dried particles of amorphous solid dispersions of aprepitant in Soluplus
and PVP and their mixtures in matrix.
Fig. 8 Raman images of a tablet surface at different times during dissolution showing the effect of Soluplus on the inhibition of crystallization. False-colors indicate
crystalline drug in pink and amorphous solid dispersion in blue. The top row is a solid dispersion of aprepitant:PVP 1:3 in the spray-dried matrix without Soluplus,
the bottom row represents the same spray-dried dispersion (aprepitant:PVP 1:3) but with physically admixed Soluplus (the final ratio of polymers in the tablet is
1:3 Soluplus:PVP), and the middle row shows the aprepitant solid dispersion with a Soluplus:PVP 1:3 combined directly in the spray-dried dispersion (i.e., nothing
added externally). The dimensions of each image are 20× 20 μm2.
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local composition and various phase transitions (e.g. crystalli-
zation) that may occur on the surface of the tablet in contact
with the dissolution medium. Finaly, a USP dissolution test
provides standardized quantitative information about the rate
of drug release. These techniques together provide an expla-
nation to the phenomenon of drug crystallization during dis-
solution and show a global picture about the different water
penetration and polymer dissolution rates that none of the
techniques alone could conclusively determine.
In the specific case of aprepitant release from a mixed-
matrix tablet, the Soluplus:PVP ratio 1:1 in the amorphous
solid dispersion has been identified by the in vitro spectroscopic
imaging approaches and dissolution tests as the best matix
combining the favorable properties of both polymers for
aprepitant dissolution. The drug dissolution rate has been
significantly enhanced, and at the same time the drug has
not precipitated during dissolution.
Crystallization was succesfully detected by each imaging
technique. More specifically, MRI was able to evaluate a new-
ly formed solid phase in gel layer while the spectroscopic im-
aging methods (ATR-FTIR spectroscopic imaging and
Raman mapping) determined the crystallization due to the
structural changes of an amorphous to a crystalline state, man-
ifested and characterized in their respective spectra.
Although the present work has dealt with specific com-
pounds (aprepitant as the API and Soluplus:PVP as polymeric
excipients), the methodology presented in this work may be
generalized for the development and optimization of other
API’s and formulations. As a general guideline for the incor-
poration of imaging methods into formulation development of
amorphous solid dispersions with a mixed polymer matrix, it
could be recommended to apply the following steps:
(i) Prepare amorphous solid dispersions with pure polymers
and theirmixtures, characterize their solid state behaviour
and stability by standard solid-state characterisation
methods (XRD, DSC, DVS). Determine the maximum
amount of API in the matrix that still forms stable amor-
phous solid dispersion.
(ii) Carry out dissolution tests from the amorphous solid dis-
persions and note any Bunusual^ behaviour such as a
change in rate of the dissolution curve or a decrease of
concentration in time, which could signal drug
crystallisation or other drug release inhibiting
phenomena.
(iii) Use MRI to determine the rate of dissolution medium
penetration into the tablet. Using mass balance and the
USP release curve, determine if the matrix hydration
rate is the rate-limiting step. If so, consider a change of
formulation to enhance the rate of penetration.
(iv) Use ATR-FTIR spectroscopic imaging to observe the
concentration profiles of the API and individual excipi-
ents in the hydrated tablet matrix. Use the ATR-FTIR
spectra to identify interactions between the API and ex-
cipients that might influence the API diffusion rate and/
or its tendency to crystallise.
(v) If there is a suspicion of API crystallisation during disso-
lution, use Raman mapping with surface x-y scans to
identify the presence of the crystalline phase and evaluate
the influence of formulation variables on the timing and
extent of API crystallisation at the surface of the tablet.
It should be realised that each API and formulation has its
specific behaviour and the time pressure of formulation devel-
opment in the industrial context may not always allow a full
and rigorous analysis to be performed. Nevertheless, we hope
to have shown that the combination of standard USP dissolu-
tion tests with several complementary spectroscopic imaging
methods is a powerful approach that can reveal the mecha-
nisms and phenomena that govern drug release from amor-
phous solid dispersions.
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